News
Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.
The CEO of Danish pharmaceutical giant Novo Nordisk, known for its blockbuster weight-loss drug Ozempic, will step down, the ...
"The Novo Nordisk Foundation is increasing its influence and has appointed its chairman, Lars Rebien Sørensen, as an observer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results